FDA Drug Approval Summary: Bevacizumab Plus FOLFOX4 as Second-Line Treatment of Colorectal Cancer

Authors:

Abstract
Learning Objectives: After completing this course, the reader will be able to: Add bevacizumab (Avastin®) to the FOLFOX4 chemotherapy regimen.Evaluate the contribution of bevacizumab and FOLFOX4 to treatment results.Understand FDA criteria for the analysis of response rate and progression-free survival. CME Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.com